Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics Q4 2024 Earnings Results & Report

Scinai Immunotherapeutics logo
$0.40 0.00 (0.00%)
Closing price 11/13/2026 03:58 PM Eastern
Extended Trading
$0.42 +0.02 (+5.25%)
As of 11/13/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scinai Immunotherapeutics reported Q4 2024 earnings on May 7, 2025. The company reported EPS of -$104.00, while revenue was $210 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
6:00 PM ET

Scinai Immunotherapeutics EPS Results

Actual EPS
-$104.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scinai Immunotherapeutics Revenue Results

Actual Revenue
$210 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Scinai Immunotherapeutics' Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedules

Earnings Documents

Scinai Immunotherapeutics Q4 2024 Earnings FAQ

Scinai Immunotherapeutics (NASDAQ:SCNI) reported earnings of -$104.00 per share for Q4 2024. The report was announced on Wednesday, May 7, 2025.

Scinai Immunotherapeutics reported revenue of $210 thousand for Q4 2024.

Scinai Immunotherapeutics' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scinai Immunotherapeutics on the company's earnings history page.

Scinai Immunotherapeutics Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Scinai Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics (NASDAQ:SCNI) Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects.

Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration. The company has focused its development efforts on therapies for inflammatory skin conditions, including plaque psoriasis, with programs directed at interleukin-17A, a cytokine associated with inflammatory and autoimmune disorders.

In addition to advancing its own product candidates, Scinai has indicated that its NanoAb platform may support partnerships and licensing opportunities for the development of other targeted immunotherapies. The company is headquartered in Israel and conducts its research and development activities through its proprietary platform and external collaborations.

View Scinai Immunotherapeutics Profile